Advertisement

PharmacoEconomics & Outcomes News

, Volume 818, Issue 1, pp 25–25 | Cite as

Pembrolizumab reduces AEs, improves quality-adjusted survival

Clinical study
  • 12 Downloads

Reference

  1. Pietanza MC, et al. Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer. PharmacoEconomics : 4 Dec 2018. Available from: URL: https://doi.org/10.1007/s40273-018-0752-0

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations